Inactive Instrument

Claritas Pharmaceuticals Toronto S.E.

Equities

KLY

CA1806341071

Biotechnology & Medical Research

Claritas Pharmaceuticals, Inc. Announces New Registered and Records Office Address

January 17, 2022 at 12:00 pm

Claritas Pharmaceuticals, Inc. announced new registered and records office address. The company's new registered and records office for corporate registry purposes is located at 5728 East Blvd., Vancouver, BC, V6M 4M4, Canada.

Latest news about Claritas Pharmaceuticals

Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	18/08/21	MT
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	26/07/21	CI
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107	21/07/21	MT
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21/07/21	CI
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23	20/07/21	MT
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index	19/07/21	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/05/21	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	30/04/21	CI
Claritas Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	29/04/21	CI
Claritas Pharmaceuticals : In Agreement with CMAX Clinical Research for Phase 1 Clinical Study of Nitric Oxide-Releasing Drug, R-107	21/04/21	MT
Claritas Pharmaceuticals, Inc. Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107	21/04/21	CI
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) added to S&P/TSX Venture Composite Index	19/04/21	CI
Claritas Pharmaceuticals : Announces Letter of Intent to Acquire Worldwide Rights to Develop R-107 Drug Compound	14/04/21	MT
Claritas Pharmaceuticals, Inc. entered into a binding Letter of Intent to acquire Exclusive Worldwide Rights of R-107 from Salzman Group Israel, Salzman Group Pty. Ltd. and Salzman Group, Inc. for $20.1 million.	13/04/21	CI
Kalytera Therapeutics, Inc. will Change its Name to Claritas Pharmaceuticals, Inc	12/04/21	CI
Kalytera Therapeutics, Inc. will Change its Ticker to CLAS from KLY	12/04/21	CI
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients	08/04/21	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107	01/04/21	CI
Claritas Pharmaceuticals, Inc. Appoints Perenlei Enkhbaatar as an Independent Member of the Company’s Board of Directors, Effective Immediately	26/03/21	CI
Claritas Pharmaceuticals, Inc. Announces Board Changes	18/03/21	CI
Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies	17/03/21	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107	12/03/21	CI
Claritas (Formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea to the Board of Directors	05/03/21	CI
Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed	04/03/21	CI
Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections	03/03/21	CI

Chart Claritas Pharmaceuticals

Duration

Period

More charts

Company Profile

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâs products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+21.68%	47.96B
IQVIA HOLDINGS INC.	+0.62%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.65%	31.6B
ICON PUBLIC LIMITED COMPANY	+20.52%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+51.48%	14.56B
MEDPACE HOLDINGS, INC.	+45.23%	14.14B
BIO-TECHNE CORPORATION	+2.14%	12.58B

Other Biotechnology & Medical Research